Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RAPT Therapeutics GCN2 compound 39
- Development stage
- Unknown
- Lead developer
- RAPT Therapeutics
01
Overview
RAPT Therapeutics GCN2 compound 39: sourced facts only. name: "In mice, compound 39 engages GCN2 at levels ≥80% with an oral dose of 15 mg/kg BID." [PMID:36127295]; target: "In mice, compound 39 engages GCN2 at levels ≥80% with an oral dose of 15 mg/kg BID." [PMID:36127295]; developer: "RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States." [PMID:36127295]; stage: "In the LL2 syngeneic mouse model, compound 39 demonstrates significant tumor growth inhibition (TGI) as a single agent." [PMID:36127295]
02
Targets
EIF2AK4 (Eukaryotic translation initiation factor 2-alpha kinase 4)
Beyond the preview
Go deeper on RAPT Therapeutics GCN2 compound 39.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAPT Therapeutics GCN2 compound 39.